Document ID: chunk:federal_register_of_legislation:F2025L00215:schedule:1:p2
Version: federal_register_of_legislation:F2025L00215
Segment Type: schedule
Provision Reference: sch 1 (pt 2/51)
Character Range: 5235–8200

suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 100 mL (S19A)  Oral  CLAVULIN-125F (GlaxoSmithKline, Canada)  DZ  MP NP  C5832 C5893  P5832 P5893  1  1     1

[7] Schedule 1, Part 1, entries for Azithromycin
omit:
Azithromycin  Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL (S19A)  Oral  Azithromycin (Zydus, USA)  DZ  MP NP  C5637     1  0     1

[8] Schedule 1, Part 1, entries for Betaxolol
omit:
Betaxolol  Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL  Application to the eye  BetoQuin  NM  MP AO             1  5     1
Betaxolol  Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL  Application to the eye  BetoQuin  NM  MP AO     P14238  2  5     1

[9] Schedule 1, Part 1, entries for Blinatumomab
substitute:
Blinatumomab  Powder for I.V. infusion 38.5 micrograms  Injection  Blincyto  AN  MP  C9369 C9519 C16292 C16308 C16334 C16341     See Note 3  See Note 3        1  D(100)

[10] Schedule 1, Part 1, entries for Cladribine in the form Tablet 10 mg
substitute:
Cladribine  Tablet 10 mg  Oral  Mavenclad  SG  MP NP  C16299 C16345  P16299 P16345  1  1        1
Cladribine  Tablet 10 mg  Oral  Mavenclad  SG  MP NP  C16299 C16345  P16299 P16345  6  1        6
Cladribine  Tablet 10 mg  Oral  Mavenclad  SG  MP NP  C16299 C16345  P16299 P16345  8  1        4

[11] Schedule 1, Part 1, entries for Dimethyl fumarate in the form Capsule (modified release) 120 mg
(a) omit from the column headed "Authorised Prescriber" (all instances): MP substitute (all instances): MP NP
(b) omit from the column headed "Circumstances" (all instances): C10139 C10140 substitute (all instances): C16315 C16323
[12] Schedule 1, Part 1, entries for Dimethyl fumarate in the form Capsule (modified release) 240 mg
(a) omit from the column headed "Authorised Prescriber" (all instances): MP substitute (all instances): MP NP
(b) omit from the column headed "Circumstances" (all instances): C10139 substitute (all instances): C16315
[13] Schedule 1, Part 1, entry for Diroximel fumarate
(a) omit from the column headed "Authorised Prescriber": MP substitute: MP NP
(b) omit from the column headed "Circumstances": C13034 13072 substitute: C16315 C16323
[14] Schedule 1, Part 1, after entry for Doxycycline in the form Tablet 100 mg (as monohydrate) [Maximum Quantity: 56; Number of Repeats: 2]
insert:
Drospirenone with ethinylestradiol  Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol and 7 inert tablets                         Oral  Yasmin  BN  MP NP        3  3     1
Drospirenone with ethinylestradiol  Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol and 7 inert tablets                         Oral  Yasmin  BN  MP NP        3  3     3
Drospirenone with ethinylestradiol  Pack containing 24 tablets 3 mg drospirenone with 20 micrograms ethinylestradiol (as betadex clathrate) and 4 inert tablets